{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T05:25:26Z","timestamp":1768109126890,"version":"3.49.0"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11,1]]},"DOI":"10.1359\/jbmr.090901","type":"journal-article","created":{"date-parts":[[2009,10,20]],"date-time":"2009-10-20T02:05:01Z","timestamp":1256004301000},"page":"1783-1788","source":"Crossref","is-referenced-by-count":13,"title":["Myeloma Bone Disease"],"prefix":"10.1093","volume":"24","author":[{"given":"Ralph D.","family":"Sanderson","sequence":"first","affiliation":[{"name":"Department of Pathology, Center for Metabolic Bone Disease and Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Epstein","sequence":"additional","affiliation":[{"name":"Department of Medicine, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024020319570411600_bib1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"2024020319570411600_bib2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1359\/jbmr.0301212","article-title":"Fracture risk in monoclonal gammopathy of undetermined significance","volume":"19","author":"Melton","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024020319570411600_bib3","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"2024020319570411600_bib4","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.bone.2008.01.027","article-title":"The pathogenesis of the bone disease of multiple myeloma","volume":"42","author":"Edwards","year":"2008","journal-title":"Bone"},{"key":"2024020319570411600_bib5","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/leu.2008.159","article-title":"Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma","volume":"22","author":"Jakob","year":"2008","journal-title":"Leukemia"},{"key":"2024020319570411600_bib6","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.1989.7.12.1909","article-title":"Mechanisms of bone destruction in multiple myeloma: The importance of an unbalanced process in determining the severity of lytic bone disease","volume":"7","author":"Bataille","year":"1989","journal-title":"J Clin Oncol"},{"key":"2024020319570411600_bib7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI115305","article-title":"Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma","volume":"88","author":"Bataille","year":"1991","journal-title":"J Clin Invest"},{"key":"2024020319570411600_bib8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05018.x","article-title":"Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation","volume":"126","author":"Lai","year":"2004","journal-title":"Br J Haematol"},{"key":"2024020319570411600_bib9","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-2141.2002.03257.x","article-title":"Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity","volume":"116","author":"Yaccoby","year":"2002","journal-title":"Br J Haematol"},{"key":"2024020319570411600_bib10","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression","volume":"98","author":"Pearse","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024020319570411600_bib11","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3109\/10428190309178765","article-title":"New insights in myeloma-induced osteolysis","volume":"44","author":"Barille-Nion","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"2024020319570411600_bib12","first-page":"1436","article-title":"Expression of receptor activator of nuclear factor {kappa}B ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma","volume":"9","author":"Heider","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2024020319570411600_bib13","first-page":"5438","article-title":"Receptor activator of nuclear factor-{kappa}B ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo","volume":"63","author":"Farrugia","year":"2003","journal-title":"Cancer Res"},{"key":"2024020319570411600_bib14","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1158\/0008-5472.CAN-07-5889","article-title":"Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand","volume":"68","author":"Wilson","year":"2008","journal-title":"Cancer Res"},{"key":"2024020319570411600_bib15","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood-2002-04-1190","article-title":"Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells","volume":"100","author":"Standal","year":"2002","journal-title":"Blood"},{"key":"2024020319570411600_bib16","doi-asserted-by":"crossref","first-page":"32628","DOI":"10.1074\/jbc.M806266200","article-title":"Heparinase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma","volume":"283","author":"Purushothaman","year":"2008","journal-title":"J Biol Chem"},{"key":"2024020319570411600_bib17","first-page":"8749","article-title":"High heparinase activity in multiple myeloma is associated with elevated microvessel density","volume":"63","author":"Kelly","year":"2003","journal-title":"Cancer Res"},{"key":"2024020319570411600_bib18","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1158\/0008-5472.CAN-05-0749","article-title":"Expression of heparinase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases","volume":"65","author":"Kelly","year":"2005","journal-title":"Cancer Res"},{"key":"2024020319570411600_bib19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cca.2006.11.024","article-title":"Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma","volume":"379","author":"Alexandrakis","year":"2007","journal-title":"Clin Chim Acta"},{"key":"2024020319570411600_bib20","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2003-11-3839","article-title":"Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: A vicious cycle between bone destruction and myeloma expansion","volume":"104","author":"Abe","year":"2004","journal-title":"Blood"},{"key":"2024020319570411600_bib21","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1182\/blood.V97.11.3349","article-title":"Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand","volume":"97","author":"Han","year":"2001","journal-title":"Blood"},{"key":"2024020319570411600_bib22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2141.2004.04864.x","article-title":"Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma","volume":"125","author":"Hashimoto","year":"2004","journal-title":"Br J Haematol"},{"key":"2024020319570411600_bib23","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.1365-2141.2003.04561.x","article-title":"Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma","volume":"123","author":"Terpos","year":"2003","journal-title":"Br J Haematol"},{"key":"2024020319570411600_bib24","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1182\/blood-2002-11-3385","article-title":"Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease","volume":"101","author":"Magrangeas","year":"2003","journal-title":"Blood"},{"key":"2024020319570411600_bib25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2002-12-3905","article-title":"Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease","volume":"102","author":"Oyajobi","year":"2003","journal-title":"Blood"},{"key":"2024020319570411600_bib26","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood.V87.4.1495.bloodjournal8741495","article-title":"Development of an in vivo model of human multiple myeloma bone disease","volume":"87","author":"Alsina","year":"1996","journal-title":"Blood"},{"key":"2024020319570411600_bib27","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1172\/JCI200113116","article-title":"Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease","volume":"108","author":"Choi","year":"2001","journal-title":"J Clin Invest"},{"key":"2024020319570411600_bib28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0304-3835(83)90145-3","article-title":"Direct bone resorbing activity of murine myeloma cells","volume":"19","author":"McDonald","year":"1983","journal-title":"Cancer Lett"},{"key":"2024020319570411600_bib29","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1365-2141.2005.05710.x","article-title":"Functional osteoclast-like transformation of cultured human myeloma cell lines","volume":"130","author":"Calvani","year":"2005","journal-title":"Br J Haematol"},{"key":"2024020319570411600_bib30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/10428190310001595696","article-title":"Osteoclast-like cell formation by circulating myeloma B lymphocytes: Role of RANK-L","volume":"45","author":"Calvani","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"2024020319570411600_bib31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/path.2078","article-title":"Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: A new type of cancer-host partnership","volume":"211","author":"Andersen","year":"2007","journal-title":"J Pathol"},{"key":"2024020319570411600_bib32","doi-asserted-by":"crossref","first-page":"6738","DOI":"10.1158\/0008-5472.CAN-09-0949","article-title":"Beta 3 Integrin subunit mediates the bone-resorbing function exerted by cultured myeloma plasma cells","volume":"69","author":"Tucci","year":"2009","journal-title":"Cancer Res"},{"key":"2024020319570411600_bib33","first-page":"836","article-title":"Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma","volume":"87","author":"Ria","year":"2002","journal-title":"Haematologica"},{"key":"2024020319570411600_bib34","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1158\/1078-0432.CCR-06-2258","article-title":"Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: A role for vascular endothelial cell growth factor and osteopontin","volume":"13","author":"Tanaka","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2024020319570411600_bib35","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.devcel.2005.03.016","article-title":"Wnt\/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis","volume":"8","author":"Day","year":"2005","journal-title":"Dev Cell"},{"key":"2024020319570411600_bib36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.gene.2004.06.044","article-title":"Wnt signaling in osteoblasts and bone diseases","volume":"341","author":"Westendorf","year":"2004","journal-title":"Gene"},{"key":"2024020319570411600_bib37","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2007-03-077685","article-title":"Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo","volume":"111","author":"Edwards","year":"2008","journal-title":"Blood"},{"key":"2024020319570411600_bib38","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood-2007-10-120253","article-title":"Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth","volume":"112","author":"Qiang","year":"2008","journal-title":"Blood"},{"key":"2024020319570411600_bib39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1476-4598-6-71","article-title":"Attenuation of WNT signaling by DKK-1 and \u22122 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF","volume":"6","author":"Fujita","year":"2007","journal-title":"Mol Cancer"},{"key":"2024020319570411600_bib40","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1182\/blood-2008-01-132134","article-title":"Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: A potential mechanism underlying osteolytic bone lesions in multiple myeloma","volume":"112","author":"Qiang","year":"2008","journal-title":"Blood"},{"key":"2024020319570411600_bib41","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: Proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"2024020319570411600_bib42","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3324\/haematol.10943","article-title":"Serum levels of OPG, RANKL and RANKL\/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations","volume":"92","author":"Goranova-Marinova","year":"2007","journal-title":"Haematologica"},{"key":"2024020319570411600_bib43","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"2024020319570411600_bib44","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1600-0609.2008.01065.x","article-title":"Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma","volume":"80","author":"Kaiser","year":"2008","journal-title":"Eur J Haematol"},{"key":"2024020319570411600_bib45","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.bone.2006.03.017","article-title":"Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia","volume":"39","author":"Li","year":"2006","journal-title":"Bone"},{"key":"2024020319570411600_bib46","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1359\/jbmr.060311","article-title":"Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass","volume":"21","author":"Morvan","year":"2006","journal-title":"J Bone Miner Res"},{"key":"2024020319570411600_bib47","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","article-title":"Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo","volume":"109","author":"Yaccoby","year":"2007","journal-title":"Blood"},{"key":"2024020319570411600_bib48","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","article-title":"Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma","volume":"114","author":"Fulciniti","year":"2009","journal-title":"Blood"},{"key":"2024020319570411600_bib49","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1182\/blood-2004-12-4940","article-title":"Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2","volume":"106","author":"Oshima","year":"2005","journal-title":"Blood"},{"key":"2024020319570411600_bib50","first-page":"567","article-title":"Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma","volume":"89","author":"Abildgaard","year":"2004","journal-title":"Haematologica"},{"key":"2024020319570411600_bib51","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1365-2141.2003.04050.x","article-title":"Comparison of five biochemical markers of bone resorption in multiple myeloma: Elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy","volume":"120","author":"Abildgaard","year":"2003","journal-title":"Br J Haematol"},{"key":"2024020319570411600_bib52","first-page":"394","article-title":"Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients","volume":"86","author":"Corso","year":"2001","journal-title":"Haematologica"},{"key":"2024020319570411600_bib53","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/bjc.1992.266","article-title":"Serum concentration of the cross-linked carboxyterminal telopeptide of type-i collagen (ICTP) is a useful prognostic indicator in multiple myeloma","volume":"66","author":"Elomaa","year":"1992","journal-title":"Br J Cancer"},{"key":"2024020319570411600_bib54","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1034\/j.1600-0609.2002.00505.x","article-title":"Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma","volume":"69","author":"Jakob","year":"2002","journal-title":"Eur J Haematol"},{"key":"2024020319570411600_bib55","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0009-8981(96)06334-6","article-title":"Biochemical bone markers in patients with multiple myeloma","volume":"253","author":"Nawawi","year":"1996","journal-title":"Clin Chim Acta"},{"key":"2024020319570411600_bib56","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","article-title":"Magnetic resonance imaging in multiple myeloma: Diagnostic and clinical implications","volume":"25","author":"Walker","year":"2007","journal-title":"J Clin Oncol"},{"key":"2024020319570411600_bib57","first-page":"300","article-title":"Myeloma and bone disease: The dangerous tango","volume":"4","author":"Epstein","year":"2006","journal-title":"Clin Adv Hematol Oncol"},{"key":"2024020319570411600_bib58","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1001\/archinte.1985.00360080125019","article-title":"Computed tomography in diagnosis and management of multiple myeloma and its variants","volume":"145","author":"Kyle","year":"1985","journal-title":"Arch Intern Med"},{"key":"2024020319570411600_bib59","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.2214\/ajr.178.6.1781429","article-title":"Multidetector CT of the spine in multiple myeloma: Comparison with MR imaging and radiography","volume":"178","author":"Mahnken","year":"2002","journal-title":"AJR Am J Roentgenol"},{"key":"2024020319570411600_bib60","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/leu.2008.336","article-title":"Pathogenesis of myeloma bone disease","volume":"23","author":"Roodman","year":"2009","journal-title":"Leukemia"},{"key":"2024020319570411600_bib61","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ajh.21310","article-title":"The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo","volume":"84","author":"Pennisi","year":"2009","journal-title":"Am J Hematol"},{"key":"2024020319570411600_bib62","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1182\/blood-2008-08-174300","article-title":"Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin\/TCF signaling","volume":"113","author":"Qiang","year":"2009","journal-title":"Blood"},{"key":"2024020319570411600_bib63","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","article-title":"Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma","volume":"135","author":"Terpos","year":"2006","journal-title":"Br J Haematol"},{"key":"2024020319570411600_bib64","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1172\/JCI16198","article-title":"Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro","volume":"111","author":"Garrett","year":"2003","journal-title":"J Clin Invest"},{"key":"2024020319570411600_bib65","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2141.2005.05733.x","article-title":"Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma","volume":"131","author":"Zangari","year":"2005","journal-title":"Br J Haematol"},{"key":"2024020319570411600_bib66","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/sj.leu.2403758","article-title":"High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: Possible role of bortezomib on osteoblast differentiation","volume":"19","author":"Shimazaki","year":"2005","journal-title":"Leukemia"},{"key":"2024020319570411600_bib67","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-08-4472","article-title":"Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: Effect on myeloma bone disease in the 5T2MM murine model of myeloma","volume":"69","author":"Deleu","year":"2009","journal-title":"Cancer Res"},{"key":"2024020319570411600_bib68","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2024020319570411600_bib69","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1359\/jbmr.081104","article-title":"Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma","volume":"24","author":"Heath","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2024020319570411600_bib70","first-page":"192","article-title":"Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model","volume":"91","author":"Yaccoby","year":"2006","journal-title":"Haematologica"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.090901","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/24\/11\/1783\/56573814\/5650241101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/24\/11\/1783\/56573814\/5650241101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:53:22Z","timestamp":1710341602000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/24\/11\/1783-1788\/7599764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,1]]},"references-count":70,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2009,11,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.090901","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,11,1]]},"published":{"date-parts":[[2009,11,1]]}}}